Advances in carnitine in chronic uremia

被引:41
作者
Guarnieri, Gianfranco [1 ]
Biolo, Gianni [1 ]
Vinci, Pierandrea [1 ]
Massolino, Benedetta [1 ]
Barazzoni, Rocco [1 ]
机构
[1] Univ Trieste, Dept Clin Morphol & Technol Sci, Div Internal Med, Trieste, Italy
关键词
D O I
10.1053/j.jrn.2006.10.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 [营养与食品卫生学];
摘要
Carnitine is a conditionally essential metabolite that plays a critical role in cell physiology. Carnitine is necessary for fatty acid transport to sites of beta-oxidation in the mitochondria, where it helps to prevent organic acid accumulation. Because of these key regulatory functions, carnitine represents a crucial determinant of mitochondrial energy metabolism, whose deficiency may lead to metabolic and clinical disturbances. Loss of carnitine through dialytic membranes occurs in maintenance hemodialysis, resulting in potential carnitine depletion and relative increments of esterified carnitine forms. Carnitine supplementation has been shown to counteract such alterations and may be associated with clinical benefit. In particular, carnitine supplementation in patients on hemodialysis may enhance response to erythropoietin, resulting in improved hematologic status. Carnitine was also reported to improve exercise tolerance and intradialytic symptoms. Carnitine supplementation may enhance insulin resistance, inflammatory and antioxidant status, protein balance, lipid profile, and cardiac function. Carnitine administration can be useful for selected patients on dialysis who do not adequately respond to standard therapy. (c) 2007 by the National Kidney Foundation, Inc.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 55 条
[1]
Reduced synthesis of muscle proteins in chronic renal failure [J].
Adey, D ;
Kumar, R ;
McCarthy, JT ;
Nair, KS .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2000, 278 (02) :E219-E225
[2]
MULTICENTER TRIAL OF L-CARNITINE IN MAINTENANCE HEMODIALYSIS-PATIENTS .2. CLINICAL AND BIOCHEMICAL EFFECTS [J].
AHMAD, S ;
ROBERTSON, HT ;
GOLPER, TA ;
WOLFSON, M ;
KURTIN, P ;
KATZ, LA ;
HIRSCHBERG, R ;
NICORA, R ;
ASHBROOK, DW ;
KOPPLE, JD .
KIDNEY INTERNATIONAL, 1990, 38 (05) :912-918
[3]
L-Carnitine: a nutritional modulator of glucocorticoid receptor functions [J].
Alesci, S ;
De Martino, MU ;
Mirani, M ;
Benvenga, S ;
Trimarchi, F ;
Kino, T ;
Chrousos, GP .
FASEB JOURNAL, 2003, 17 (09) :1553-+
[4]
BIOLO G, 2006, 13 INT C NUTR MET RE, P41
[5]
Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients [J].
Brass, EP ;
Adler, S ;
Sietsema, KE ;
Hiatt, WR ;
Orlando, AM ;
Amato, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (05) :1018-1028
[6]
Antioxidant effect of L-carnitine and its short chain esters -: Relevance for the protection from oxidative stress related cardiovascular damage [J].
Calò, LA ;
Pagnin, E ;
Davis, PA ;
Semplicini, A ;
Nicolai, R ;
Calvani, M ;
Pessina, AC .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 107 (01) :54-60
[7]
Carnitine replacement in end-stage renal disease and hemodialysis [J].
Calvani, M ;
Benatti, P ;
Mancinelli, A ;
D'Iddio, S ;
Giordano, V ;
Koverech, A ;
Amato, A ;
Brass, EP .
CARNITINE: THE SCIENCE BEHIND A CONDITIONALLY ESSENTIAL NUTRIENT, 2004, 1033 :52-66
[8]
Chazot C, 2003, CLIN NEPHROL, V59, P24
[9]
HIGH-DOSE L-CARNITINE IMPROVES IMMUNOLOGICAL AND METABOLIC PARAMETERS IN AIDS PATIENTS [J].
DESIMONE, C ;
TZANTZOGLOU, S ;
FAMULARO, G ;
MORETTI, S ;
PAOLETTI, F ;
VULLO, V ;
DELIA, S .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1993, 15 (01) :1-12
[10]
DILISA F, 2005, CARNITINE SYSTEM, P21